About: TRAIL-based gene delivery and therapeutic strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: TRAIL-based gene delivery and therapeutic strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	TRAIL-based gene delivery and therapeutic strategies
Creator	Li, Jian Huang, Yong-Zhuo Wang, Hui-Yuan Zhong, Hui-Hai
Source	PMC
abstract	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), also known as APO2L, belongs to the tumor necrosis factor family. By binding to the death receptor 4 (DR4) or DR5, TRAIL induces apoptosis of tumor cells without causing side toxicity in normal tissues. In recent years TRAIL-based therapy has attracted great attention for its promise of serving as a cancer drug candidate. However, the treatment efficacy of TRAIL protein was under expectation in the clinical trials because of the short half-life and the resistance of cancer cells. TRAIL gene transfection can produce a “bystander effect” of tumor cell killing and provide a potential solution to TRAIL-based cancer therapy. In this review we focus on TRAIL gene therapy and various design strategies of TRAIL DNA delivery including non-viral vectors and cell-based TRAIL therapy. In order to sensitize the tumor cells to TRAIL-induced apoptosis, combination therapy of TRAIL DNA with other drugs by the codelivery methods for yielding a synergistic antitumor efficacy is summarized. The opportunities and challenges of TRAIL-based gene delivery and therapy are discussed.
has issue date	2019-08-23(xsd:dateTime)
bibo:doi	10.1038/s41401-019-0287-8
bibo:pmid	31444476
has license	cc-by
sha1sum (hex)	876e3b3d4d06aacf2cfab1517ee653d15e2e9bc5
schema:url	https://doi.org/10.1038/s41401-019-0287-8
resource representing a document's title	TRAIL-based gene delivery and therapeutic strategies
has PubMed Central identifier	PMC6889127
has PubMed identifier	31444476
schema:publication	Acta Pharmacol Sin
resource representing a document's body	covid:876e3b3d4d06aacf2cfab1517ee653d15e2e9bc5#body_text
is schema:about of	named entity 'tumor cells' named entity 'DNA' named entity 'DEATH RECEPTOR 4' named entity 'PROTEIN ' named entity 'EFFECT' named entity 'REVIEW' named entity 'GREAT' named entity 'OTHER DRUGS' named entity 'DR5' named entity 'POTENTIAL' covid:arg/876e3b3d4d06aacf2cfab1517ee653d15e2e9bc5 named entity 'family' named entity 'candidate' named entity 'death receptor' named entity 'However' named entity 'serving' named entity 'TRAIL' named entity 'potential' named entity 'synergistic' named entity 'protein' named entity 'tumor necrosis factor' named entity 'cancer cells' named entity 'TRAIL' named entity 'TRAIL' named entity 'combination therapy' named entity 'tumor cells' named entity 'TRAIL' named entity 'tumor cells' named entity 'intracellular' named entity 'Upregulation' named entity 'monensin' named entity 'biocompatible' named entity 'polyethyleneimine' named entity 'complexation' named entity 'intracranial tumors' named entity 'plasmid DNA' named entity 'host cells' named entity 'sensitizing' named entity 'nanoparticles' named entity 'DR4' named entity 'cancer stem cell' named entity 'caspase-3' named entity 'Polyethyleneimine' named entity 'TRAIL' named entity 'AFP' named entity 'proapoptotic' named entity 'Bcl-2' named entity 'apoptosis' named entity 'cellular homeostasis' named entity 'TRAIL' named entity 'heat shock protein' named entity 'TRAIL' named entity 'NPs' named entity 'apoptosis' named entity 'OPG' named entity 'glioma' named entity 'polyplex' named entity 'copolymerization' named entity 'clinical trials' named entity 'DR5' named entity 'toxicity' named entity 'hydrolytically' named entity 'molecular-weight' named entity 'HSV' named entity 'DISC' named entity 'delivery systems' named entity 'cationic liposome' named entity 'esterase' named entity 'toxicity' named entity 'cell cycle arrest' named entity 'clinical trials' named entity 'apoptosis' named entity 'serum' named entity 'peritoneal' named entity 'melanoma' named entity 'tumor' named entity 'peptide' named entity 'death receptors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software